PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)

被引：0
|
作者：
Liu, S. -Y. M. [1 ,2 ]
Deng, J. -Y. [3 ]
Yan, H. -H. [3 ]
Yang, M. -Y. [3 ]
Xu, C. -R. [3 ]
Zheng, M. -Y. [3 ]
Gan, B. [3 ]
Zhang, X. -C. [3 ]
Tu, H. -Y. [3 ]
Yang, J. -J. [3 ]
Chen, H. -J. [3 ]
Wang, B. -C. [3 ]
Li, Y. [1 ,4 ]
Zhou, Q. [2 ,3 ]
Wu, Y. -L. [2 ,3 ]
机构：
[1] Jinan Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China
[2] Chinese Thorac Oncol Grp CTONG, Guangzhou, Peoples R China
[3] Southern Med Univ, Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[4] Jinan Univ, Sch Med, Inst Hematol, Key Lab Regenerat Med,Minist Educ, Guangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
non-small cell lung cancer; pembrolizumab; sintilimab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
WS02.13
引用
收藏
页码：S38 / S39
页数：2
相关论文
共 50 条
  • [21] Case Report: Efficacy of anlotinib and sintilimab in treating lung adenocarcinoma with RET fusion and PD-L1 expression
    Bao, Hejing
    Zhang, Jiani
    Wang, Yuhuan
    Chen, Zhiting
    Luo, Xi
    Li, Ting
    Su, Haoran
    Bao, Hehong
    Cao, Xiaolong
    Lin, Liping
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [22] Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations
    Justin A. Chen
    Jonathan W. Riess
    Current Treatment Options in Oncology, 2020, 21
  • [23] Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%
    Wang, Liting
    Peng, Ye
    Zeng, Xiaohui
    Peng, Liubao
    Li, Sini
    Qin, Shuxia
    Wan, Xiaomin
    Tan, Chongqing
    ADVANCES IN THERAPY, 2021, 38 (08) : 4354 - 4365
  • [24] T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer
    Shah, Manish A.
    Kojima, Takashi
    Hochhauser, Daniel
    Enzinger, Peter
    Raimbourg, Judith
    Hollebecque, Antoine
    Lordick, Florian
    Kim, Sung-Bae
    Tajika, Masahiro
    Lockhart, Albert Craig
    Arkenau, Hendrick-Tobias
    El-Hajbi, Farid
    Gupta, Mukul
    Pfeiffer, Per
    Bhagia, Pooja
    Cao, Zhu Alexander
    Lunceford, Jared
    Suryawanshi, Shailaja
    Ayers, Mark
    Marton, Matthew J.
    Kato, Ken
    FUTURE ONCOLOGY, 2022, 18 (25) : 2783 - 2790
  • [25] Complete response to pembrolizumab as a single agent in a patient with stage III NSCLC with high PD-L1 expression: a case report
    Medusa, Paola Maria
    Gilli, Marina
    Notizia, Luca
    Pagliaro, Raffaella
    Carro, Nicola
    Moriello, Alessandro
    D'Agnano, Vito
    Bianco, Andrea
    Perrotta, Fabio
    Vitiello, Fabiana
    MONALDI ARCHIVES FOR CHEST DISEASE, 2023, 93 (04)
  • [26] Correlation Between PD-L1 Gene Promoter Polymorphisms and Expression of PD-L1 mRNA and Protein in NSCLC Patients.
    Kucharczyk, T.
    Grenda, A.
    Krawczyk, P.
    Nicos, M.
    Jarosz, B.
    Szumilo, J.
    Reszka, K.
    Trojanowski, T.
    Milanowski, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S732 - S732
  • [27] Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing
    Jones, Lauren
    Rittberg, Rebekah
    Leung, Bonnie
    Shokoohi, Aria
    Pender, Alexandra
    Wong, Selina
    Al-Hashami, Zamzam
    Wang, Ying
    Ho, Cheryl
    CURRENT ONCOLOGY, 2022, 29 (11) : 8686 - 8692
  • [28] First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
    Zhou, Yixin
    Lin, Zuan
    Zhang, Xuanye
    Chen, Chen
    Zhao, Hongyun
    Hong, Shaodong
    Zhang, Li
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [29] Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC : Any Differences Based on Histology?
    Meshulami, Noy
    Tavolacci, Sooyun
    de Miguel-Perez, Diego
    Rolfo, Christian
    Mack, Philip C.
    Hirsch, Fred R.
    CLINICAL LUNG CANCER, 2023, 24 (05) : 401 - 406
  • [30] Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients
    Bracci, Stefano
    Dolciami, Miriam
    Trobiani, Claudio
    Izzo, Antonella
    Pernazza, Angelina
    D'Amati, Giulia
    Manganaro, Lucia
    Ricci, Paolo
    RADIOLOGIA MEDICA, 2021, 126 (11): : 1425 - 1433
12345